For decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals.

That script is breaking.

In today’s precision medicine transactions, the real asset is data. Longitudinal patient records, real-world evidence, and genomic datasets are now central to valuation. But unlike traditional IP, data comes with strings attached. Privacy laws, patient consent, and transfer restrictions can quietly determine whether that data is an asset or a liability.

In this episode of KLF Deep Dive, we explore why clinical data is being treated as the new IP in biotech M&A, how weak consent frameworks can destroy deal value, and what acquirers should be asking during diligence before it’s too late.

If you work in biotech, pharma, corporate development, or private equity, this episode breaks down a risk that is reshaping how deals get priced and structured.

Listen in, and reach out if this issue is sitting inside one of your transactions.

Episode Highlights

• Why patents alone no longer drive biotech valuations
• How precision medicine changed the M&A playbook
• Clinical data as a regulated asset
• Patient consent and data transfer risks
• When valuable datasets become compliance liabilities
• What smart buyers are doing differently in diligence

Support the show

www.kulkarnilawfirm.com